Valproic Acid

"Valproic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of voltage dependent sodium channels.

Descriptor ID	D014635
MeSH Number(s)	D02.241.081.944.509.900 D10.251.400.895.593.900
Concept/Terms	Valproic Acid Valproic Acid Propylisopropylacetic Acid 2-Propylpentanoic Acid 2 Propylpentanoic Acid Divalproex Depakene Depakene Depakine Convulsofin Convulsofin Depakote Depakote Vupral Vupral Divalproex Sodium Divalproex Sodium Semisodium Valproate Valproic Acid, Sodium Salt (2:1) Ergenyl Ergenyl Magnesium Valproate Magnesium Valproate Valproate Valproate Valproate Sodium Valproate Sodium Sodium Valproate Valproate, Sodium Calcium Valproate Calcium Valproate Valproate, Calcium Valproate Calcium Dipropyl Acetate Dipropyl Acetate

Below are MeSH descriptors whose meaning is more general than "Valproic Acid".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Carboxylic Acids [D02.241]
Acids, Acyclic [D02.241.081]
Valerates [D02.241.081.944]
Pentanoic Acids [D02.241.081.944.509]
Valproic Acid [D02.241.081.944.509.900]
Lipids [D10]
Fatty Acids [D10.251]
Fatty Acids, Volatile [D10.251.400]
Valerates [D10.251.400.895]
Pentanoic Acids [D10.251.400.895.593]
Valproic Acid [D10.251.400.895.593.900]

Below are MeSH descriptors whose meaning is related to "Valproic Acid".

Below are MeSH descriptors whose meaning is more specific than "Valproic Acid".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Valproic Acid" by people in this website by year, and whether "Valproic Acid" was a major or minor topic of these publications.

Bar chart showing 42 publications over 20 distinct years, with a maximum of 6 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	3	0	3
1999	1	0	1
2002	3	0	3
2003	1	0	1
2005	0	1	1
2006	0	1	1
2007	1	2	3
2008	2	4	6
2009	0	1	1
2010	2	2	4
2011	1	0	1
2012	1	0	1
2013	2	1	3
2014	1	2	3
2017	1	1	2
2018	0	1	1
2020	1	1	2
2021	1	1	2
2022	0	2	2
2023	1	0	1

Below are the most recent publications written about "Valproic Acid" by people in Profiles.

Wilmshurst JM, Sperling MR. Equity in access to antiseizure medications: Who has the right to decide and what are the consequences of crisis decisions? Epilepsia. 2023 08; 64(8):2011-2013.

View in: PubMed
Kukal S, Bora S, Kanojia N, Singh P, Paul PR, Rawat C, Sagar S, Bhatraju NK, Grewal GK, Singh A, Kukreti S, Satyamoorthy K, Kukreti R. Valproic Acid-Induced Upregulation of Multidrug Efflux Transporter ABCG2/BCRP via PPARa-Dependent Mechanism in Human Brain Endothelial Cells. Mol Pharmacol. 2023 03; 103(3):145-157.

View in: PubMed
Farazdaghi M, Razavizadegan SMA, Moghimi M, Asadi-Pooya AA. Efficacy of Valproic Acid Against Coronavirus Disease 2019 Infection or Severity: A Pilot Study. Clin Neuropharmacol. 2022 Nov-Dec 01; 45(6):175-176.

View in: PubMed
Asadi-Pooya AA, Rostaminejad M, Zeraatpisheh Z, Mirzaei Damabi N. Cosmetic adverse effects of antiseizure medications; A systematic review. Seizure. 2021 Oct; 91:9-21.

View in: PubMed
Pitt B, Sutton NR, Wang Z, Goonewardena SN, Holinstat M. Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19. Eur J Pharmacol. 2021 May 05; 898:173988.

View in: PubMed
Ilieva HS, Newman JW, Fields RK, Croom JE. Valproic acid and zonisamide induced hyperammonemic encephalopathy. Clin Neurol Neurosurg. 2020 09; 196:105894.

View in: PubMed
Asadi-Pooya AA, Homayoun M. Tonic-clonic seizures in idiopathic generalized epilepsies: Prevalence, risk factors, and outcome. Acta Neurol Scand. 2020 Jun; 141(6):445-449.

View in: PubMed
Johannesen KM, Gardella E, Linnankivi T, Courage C, de Saint Martin A, Lehesjoki AE, Mignot C, Afenjar A, Lesca G, Abi-Warde MT, Chelly J, Piton A, Merritt JL, Rodan LH, Tan WH, Bird LM, Nespeca M, Gleeson JG, Yoo Y, Choi M, Chae JH, Czapansky-Beilman D, Reichert SC, Pendziwiat M, Verhoeven JS, Schelhaas HJ, Devinsky O, Christensen J, Specchio N, Trivisano M, Weber YG, Nava C, Keren B, Doummar D, Schaefer E, Hopkins S, Dubbs H, Shaw JE, Pisani L, Myers CT, Tang S, Tang S, Pal DK, Millichap JJ, Carvill GL, Helbig KL, Mecarelli O, Striano P, Helbig I, Rubboli G, Mefford HC, M?ller RS. Defining the phenotypic spectrum of SLC6A1 mutations. Epilepsia. 2018 02; 59(2):389-402.

View in: PubMed
Mahmoudi M, Friedman D, Vendrame M, Kothare SV. A Case of Recurrent Hypersomnia With Autonomic Dysfunction. J Clin Sleep Med. 2017 Jul 15; 13(7):923-924.

View in: PubMed
Spiegel DR, Samaras A, Oldham CL, Kaloji M, Warren A, Maj S, Husain SR, Solomons JI, Le S. A Likely Case of Limbic Encephalitis in a Patient With Voltage-Gated Potassium Channel Complex Antibody, Without a Known Antigenic Target: A Review of the Disease State and Value of Antibody Titers. Psychosomatics. 2017 Nov - Dec; 58(6):669-675.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement